NPPA panel pegs price of Hetero Labs HIV drug Darunavir Ethanolate at Rs 190.44 per tablet

Published On 2021-05-28 12:16 GMT | Update On 2021-05-28 12:16 GMT

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) Committee has suggested the retail price of each film-coated tablet containing Darunavir Ethanolate, which is equivalent to Darunavir IP 800 mg plus Ritonavir IP 100 mg, at Rs. 190.44 per tablet excluding GST, manufactured by Hetero Labs Ltd. and marketed by Cipla Ltd.

This came after the Multidisciplinary Committee of Experts deliberated on the retail price fixation of the popular protease inhibitor Darunavir Ethanolate, which is used to treat HIV.

Darunavir Ethanolate is the ethanolate form of darunavir, which is a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor. Darunavir, in general, is used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection.

Darunavir specifically targets and binds to the active site of HIV-1 protease after oral administration, inhibiting dimerization and catalytic activity of HIV-1 protease.In HIV-infected cells, this suppresses the proteolytic cleavage of viral Gag and Gag-Pol polyproteins. This suppression results in the synthesis of immature, non-infectious viral proteins that are unable to form mature virions and prevents HIV replication.

Due to in vitro data confirming its capacity to battle SARS-CoV-2, the coronavirus responsible for COVID-19, darunavir is also being explored as a potential therapy for Covid 19.

Also Read: No benefit of Lopinavir–Ritonavir combo in severe COVID-19, says NEJM

After detailed deliberation, the committee recommended the retail price of each film-coated tablet containing Darunavir Ethanolate eq. to Darunavir IP 800 mg + Ritonavir IP 100 mg for M/s Hetero Labs Ltd. (manufacturer) and M/s Cipla Ltd. (marketer) at Rs. 190.44 per tablet excluding GST as detailed below:

Sl. No.	Company	Price To Retailer (PTR) as per Fom-V submitted by the company	PTR per tablet
1	Hetero Healthcare Ltd	Rs. 5109.29 per 30 tablet	Rs.170.30
2	Emcure Pharmaceuticals Ltd	Rs. 4741.20 per 30 tablet	Rs. 158.04
Therefore, average PTR			Rs. 164.17
Add: 16% retailer margin			Rs. 26.27
Worked out the retail price per tablet			Rs. 190.44

Also Read: NPPA panel suggests price Of Ivabradine Hydrochloride tablet marketed by Lupin

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medical Dialogues Team

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

NPPA panel pegs price of Hetero Labs HIV drug Darunavir Ethanolate at Rs 190.44 per tablet

Similar News

Russia's Enteromix Cancer Vaccine Shows 100% Success in Trial, Awaits Final Nod for Public Use

Mankind Pharma wins CDSCO nod to start Phase 1 trials of Autoimmune drug candidate

India seeks to boost drug exports to semi regulated markets in Africa, Latin America, Southeast Asia

Jubilant Ingrevia appoints Sonia Dharap as Vice President - Sales, Business Development (US)

EMA warns of sharp rise in illegal medicines sold in EU

Indegene opens new center in Pune, boosts India presence

Indian medical devices share increased from 10% to 30% of domestic requirements in last 5 years: DoP Secretary

AstraZeneca announces Rs 176 crore investments in India to expand Chennai GITC